HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

Main Inclusion Criteria: * Adult male and female patients w or w/o dialysis treatment * Stable i.v. or s.c. maintenance therapy with an EU-approved ESA treatment or ESA naïve. * Adequate iron substitution Main Exclusion Criteria: * History of Pure Red Cell Aplasia (PRCA) or anti-erythropoietin (EPO) antibodies * Contraindications for ESA therapy * Serum albumin \< 3.0 g/dL * Immunocompromized patients (immunosuppressive treatment, chemotherapy) * Hepatitis C infection on an active treatment or hepatitis B or human immunodeficiency virus (HIV) infection * Systemic lupus erythematosus * Symptomatic congestive heart failure, Unstable angina pectoris, or myocardial infarction within 6 months * History of malignancy of any organ system within the last 5 years * History of use of any non-EU approved ESA